Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight

10/07/2021 | 07:25am EST


ę MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
07:03aTakeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..
BU
04:18aTakeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd ..
AQ
12/07Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd ..
BU
12/07Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd ..
CI
12/03Takeda's LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years a..
AQ
12/03Japanese Shares Close With Gains on Japan Services Data
MT
12/02Takeda Says Livtencity Commercially Available in the US for Patients 12 Years and Older
MT
12/02Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Ye..
BU
12/02Takeda Pharmaceutical Company Limited Announces its LIVTENCITY? Now Available for Certa..
CI
12/02Takeda Pharmaceutical Buys Back Shares for $441 Million
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 413 B 30 018 M 30 018 M
Net income 2022 214 B 1 886 M 1 886 M
Net Debt 2022 3 345 B 29 418 M 29 418 M
P/E ratio 2022 22,6x
Yield 2022 5,75%
Capitalization 4 880 B 42 868 M 42 911 M
EV / Sales 2022 2,41x
EV / Sales 2023 2,28x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 133,00 JPY
Average target price 4 065,71 JPY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-16.56%43 194
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215